UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Recruiting
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Recruiting
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Chordoma
Schwannoma (grade 1)
Craniopharyngioma
Oligodendroglioma
Meningioma
Pituitary Tumor
This observational study will collect data to better understand our patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis.
Recruiting
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Recruiting
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Medulloblastoma
Ependymoma
This phase I clinical trial will study a novel drug called ALRN-6924 for treating children and young adults with recurrent or refractory solid tumors, brain tumors, lymphoma or leukemia. 
Recruiting
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Glioma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)

Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings.

Recruiting
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary

This phase I/II  clinical trial will evaluate REGN2810 (also called cemiplimab) in combination with radiation therapy as a treatment for pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), ne

Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Diffuse astrocytoma (grade II)
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.
Recruiting

Stay Informed